- Risk factors
- Diseases Caused by Pneumococci
- Key Points
- More Information
- Drugs Mentioned In This Article
Streptococcus pneumoniae (pneumococci) are gram-positive, alpha-hemolytic, aerobic, encapsulated diplococci. In the US, pneumococcal infection annually causes about 7 million cases of otitis media, 500,000 cases of pneumonia, 50,000 cases of sepsis, 3,000 cases of meningitis, and 40,000 deaths. Diagnosis is by Gram stain and culture. Treatment depends on the resistance profile and includes a beta-lactam, a macrolide, a respiratory fluoroquinolone, and sometimes vancomycin.
Pneumococci are fastidious microorganisms that require catalase to grow on agar plates. In the laboratory, pneumococci are identified by
Pneumococci commonly colonize the human respiratory tract, particularly in winter and early spring. Spread is via airborne droplets.
True epidemics of pneumococcal infections are rare; however, some serotypes seem to be associated with outbreaks in certain (eg, military, institutional) populations.
The pneumococcus capsule consists of a complex polysaccharide that determines serologic type and contributes to virulence and pathogenicity. Virulence varies somewhat within serologic types because of genetic diversity.
Currently, > 90 different pneumococcal serotypes have been identified based on their reaction with type-specific antisera. Most serious infections are caused by a small number of serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) that are included in the 13-valent pneumococcal conjugate vaccine. These serotypes cause about 90% of invasive infections in children and 60% in adults. However, these patterns are slowly changing, in part because of the widespread use of polyvalent vaccine. Serotype 19A, which is highly virulent and multidrug-resistant, has emerged as an important cause of respiratory tract infection and invasive disease; it is thus now included in the 13-valent pneumococcal conjugate vaccine.
Patients most susceptible to serious and invasive pneumococcal infections are
Those with chronic illness (eg, chronic cardiorespiratory disease, diabetes, liver disease, alcoholism)
Those with immunosuppression (eg, HIV)
Those with functional or anatomic asplenia
Those with sickle cell disease
Residents of long-term care facilities
Aborigines, Alaskan natives, and certain American Indian populations
The elderly, even those without other disease, tend to have a poor prognosis with pneumococcal infections.
Damage to the respiratory epithelium by chronic bronchitis or common respiratory viral infections, notably influenza, may predispose to pneumococcal invasion.
Pneumococcal diseases include
Primary pneumococcal infection usually involves the middle ear or lungs.
The diseases listed below are further discussed elsewhere in The Manual.
Pneumococcal bacteremia can occur in immunocompetent and immunosuppressed patients; patients who have had splenectomy are at particular risk.
Bacteremia may be the primary infection, or it may accompany the acute phase of any focal pneumococcal infection. When bacteremia is present, secondary seeding of distant sites may cause infections such as septic arthritis, meningitis, and endocarditis.
Despite treatment, the overall case-fatality rate for bacteremia is
Risk of death is highest during the first 3 days.
Pneumonia is the most frequent serious infection caused by pneumococci; it may manifest as lobar pneumonia or, less commonly, as bronchopneumonia. About 4 million cases of community-acquired pneumonia occur each year in the US; when community-acquired pneumonia requires hospitalization, pneumococci are the most common etiologic agent in patients of all ages.
Pleural effusion occurs in up to 40% of patients, but most effusions resolve during drug treatment. Only about 2% of patients develop empyema, which may become loculated, thick, and fibrinopurulent; empyema has been most commonly associated with S. pneumoniae serotype 1. Lung abscess due to S. pneumoniae is uncommon in adults but occurs more frequently in children; serotype 3 is the usual pathogen, but other pneumococcal serotypes may be involved.
Acute otitis media in infants (after the neonatal period) and children is caused by pneumococci in about 30 to 40% of cases. More than one third of children in most populations develop acute pneumococcal otitis media during the first 2 yr of life, and pneumococcal otitis media commonly recurs. Relatively few serotypes of S. pneumoniae are responsible for most cases. After universal immunization of infants in the US beginning in 2000, nonvaccine serotypes of S. pneumoniae (particularly serotype 19A—not in the original protein-conjugated pneumococcal vaccine) have become the most common pneumococcal cause of acute otitis media.
Intracranial complications are rare in developed countries but may include meningitis, epidural abscess, brain abscess, lateral venous sinus thrombosis, cavernous sinus thrombosis, subdural empyema, and carotid artery thrombosis.
Paranasal sinusitis may be caused by pneumococci and may become chronic and polymicrobic.
Most commonly, the maxillary and ethmoid sinuses are affected. Infection of the sinuses causes pain and purulent discharge and may extend into the cranium, causing the following complications:
Acute purulent meningitis is frequently caused by pneumococci and may be secondary to bacteremia from other foci (notably pneumonia); direct extension from infection of the ear, mastoid process, or paranasal sinuses; or basilar fracture of the skull involving one of these sites or the cribriform plate (usually with cerebrospinal fluid leakage), thus giving bacteria in the paranasal sinuses, nasopharynx, or middle ear access to the CNS.
Typical meningitis symptoms (eg, headache, stiff neck, fever) occur.
Complications after pneumococcal meningitis include
Acute bacterial endocarditis may result from pneumococcal bacteremia, even in patients without valvular heart disease, but is rare.
Pneumococcal endocarditis may produce a corrosive valvular lesion, with sudden rupture or fenestration, leading to rapidly progressive heart failure.
Pneumococci are readily identified by their typical appearance on Gram stain as lancet-shaped diplococci.
The characteristic capsule can be best detected using the Quellung test. In this test, application of antiserum followed by staining with India ink causes the capsule to appear like a halo around the organism. The capsule is also visible in smears stained with methylene blue.
Culture confirms identification; antimicrobial susceptibility testing should be done. Serotyping and genotyping of isolates can be helpful for epidemiologic reasons (eg, to follow the spread of specific clones and antimicrobial resistance patterns). Differences in virulence within a serotype may be distinguished by techniques such as pulsed-field gel electrophoresis and multilocus sequence typing.
If pneumococcal infection is suspected, initial therapy pending susceptibility studies should be determined by local resistance patterns.
Although preferred treatment for pneumococcal infections is a beta-lactam or macrolide antibiotic, treatment has become more challenging because resistant strains have emerged. Strains highly resistant to penicillin, ampicillin, and other beta-lactams are common worldwide. The most common predisposing factor to beta-lactam resistance is use of these drugs within the past several months. Resistance to macrolide antibiotics has also increased significantly; these drugs are no longer recommended as monotherapy for hospitalized patients with community-acquired pneumonia.
Intermediately resistant organisms may be treated with usual or high doses of penicillin G or another beta-lactam.
Seriously ill patients with nonmeningeal infections caused by organisms that are highly resistant to penicillin can often be treated with ceftriaxone, cefotaxime, or ceftaroline. Very high doses of parenteral penicillin G (20 to 40 million units/day IV for adults) also work, unless the minimum inhibitory concentration of the isolate is very high. Fluoroquinolones (eg, moxifloxacin, levofloxacin, gemifloxacin) are effective for respiratory infections with highly penicillin-resistant pneumococci in adults. Evidence suggests that the mortality rate for bacteremic pneumococcal pneumonia is lower when combination therapy (eg, macrolide plus beta-lactam) is used.
All penicillin-resistant isolates have been susceptible to vancomycin so far, but parenteral vancomycin does not always produce concentrations in CSF adequate for treatment of meningitis (especially if corticosteroids are also being used). Therefore, in patients with meningitis, ceftriaxone or cefotaxime, rifampin, or both are commonly used with vancomycin.
Infection produces type-specific immunity that does not generalize to other serotypes. Otherwise, prevention involves
Two pneumococcal vaccines are available:
Pneumococcal conjugated vaccine (PCV13): A conjugated vaccine against 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Pneumococcal polysaccharide vaccine (PPSV23): A polyvalent polysaccharide vaccine directed against the 23 serotypes that account for > 90% of serious pneumococcal infections in adults and children (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F)
The vaccine schedules vary depending on age and medical conditions present in the patient.
Pneumococcal conjugated vaccine (PCV13) is recommended for the following:
All children aged 2 mo to 6 yr (see Table: Recommended Immunization Schedule for Ages 0–6 yr)
Adults ≥ 65 yr
Patients aged 6 to 64 yr with certain medical conditions
Certain medical conditions put patients at high risk of pneumococcal infections; they include the following:
A cochlear implant
Sickle cell disease or another hemoglobinopathy
Congenital or acquired asplenia
Immunocompromising conditions (eg, congenital immunodeficiency, chronic renal failure, nephrotic syndrome, HIV infection, leukemia, lymphomas, generalized cancer, use of immunosuppressants, solid organ transplant)
Pneumococcal polysaccharide vaccine (PPSV23) is recommended for the following:
Additional vaccine criteria for patients aged 2 to 64 yr include the following:
Adults aged 19 to 64 yr who smoke should be given 1 dose of PPSV23.
For functional or anatomic asplenic children < 5 yr prophylactic penicillin V 125 mg po bid is recommended. The duration for chemoprophylaxis is empiric, but some experts continue prophylaxis throughout childhood and into adulthood for high-risk patients with asplenia. Penicillin 250 mg po bid is recommended for older children or adolescents for at least 1 yr after splenectomy.
Pneumococci cause many cases of otitis media and pneumonia and can also cause meningitis, sinusitis, and septic arthritis.
Patients with chronic respiratory tract disease or asplenia are at high risk of serious and invasive pneumococcal infections, as are immunocompromised patients.
Treat uncomplicated or mild infection with a beta-lactam or macrolide antibiotic.
Because resistance to beta-lactam and macrolide antibiotics is increasing, seriously ill patients may be treated with an advanced-generation cephalosporin (eg, ceftriaxone, cefotaxime, ceftaroline) and/or a respiratory fluoroquinolone (eg, moxifloxacin, levofloxacin, gemifloxacin).
Severe or bacteremic pneumococcal pneumonia is treated with combination therapy (eg, macrolide plus beta-lactam).
Routine vaccination is recommended for all children aged 6 wk through 59 mo, all adults ≥ 65 yr, and people of other ages with certain risk factors.
Drug NameSelect Trade
levofloxacinIQUIX, LEVAQUIN, QUIXIN
ampicillinNo US brand name